Conference dates: MAY 15-19, 2023

Booth: 416

Location: Hynes Convention Center (Boston, MA)

Poster sessions

Poster 1 Title: LSAXT: Extending the Applications Space of HT-SPR

Presenter: Nicholas Abuid, Field Application Scientist, Carterra

Abstract: High-throughput surface plasmon resonance (HT-SPR) has transformed how real-time, label-free binding is deployed in modern, sophisticated drug discovery processes. These transformations have come from both substantial gains in throughput and reduced sample amounts. Described here is an expansion to the breadth of assays and applications HT-SPR can address by improvements in sensitivity and overall data quality, embodied in the new Carterra LSAXT. With these improvements, the versatility of HT-SPR can now be more easily leveraged in more challenging assay types such as PROTAC®s and kinase inhibitors.

Poster 2 Title: Use of High Throughput SPR to Characterize Antibodies To Common Cancer Biomarkers

Presenter: Nicholas Abuid, Field Application Scientist, Carterra

Abstract: As a disease of misregulation, cancer is characterized both genetically and proteomically, requiring high quality tools to dissect the change difference between cell states. Among the reagents used to characterize biological systems at the protein level, antibodies are routinely applied, and engineered versions have proven useful for treating multiple therapeutic indications. We have generated a human proteome wide toolbox of polyclonal antibodies, identifying three antigenic 14mer sequences within each of the 20,000+ open reading frames at N-terminal, middle and C-terminal regions. Using a high throughput SPR system, Carterra® LSA®, we are able to define average on-rates, off-rates, and KD’s for pAb’s generated to important cancer regulators and biomarkers, including KRAS, STAT3, and Gli1. Due to the small size of the peptide targets, the kinetics of the observed interactions with polyclonal antibodies exhibit remarkable 1:1 fit typically observed when measuring monoclonal antibody affinities. The platform is a sensitive system capable of both identifying multiple antibody-antigen interactions with KD in the nanomolar to picomolar range, but also as a mass screening tool for developing de novo antibody pairs. We define the kinetic characteristics of these antibody reagents relative to performance in western blotting specifically. Improving the characterization of such widely used tools is critical for advancing translational opportunities into use in the clinic.

Poster 3 Title: Large-scale Characterization of Drug Candidates Against Transmembrane Receptors using HT-SPR

Presenter: Nicholas Abuid, Field Application Scientist, Carterra

Abstract: Membrane targets make up a substantial part of the overall “undruggable” therapeutic space that has recently garnered widespread interest. Despite encouraging improvements in the tools to screen for therapeutics against membrane-bound targets, there are still many practical limitations owing to the challenges of working with proteins that are not highly stable outside of the cellmembrane environment. High-throughput surface plasmon resonance (HT-SPR) is a powerful technique that is transforming characterization workflows and enabling a greater breadth and depth of information for drug candidates. Here we demonstrate the ability to quantitatively assess binding kinetics for panels of antibodies against membrane receptors in several formats. This workflow highlights opportunities to perform detailed binding characterization for up to thousands of drug candidates in parallel.